SAN DIEGO, Jan. 21, 2015 /PRNewswire/ -- Halozyme
Therapeutics, Inc. (NASDAQ: HALO) today announced the appointment
of Jean-Pierre Bizzari, M.D. to its
Board of Directors. Dr. Bizzari brings extensive experience in
oncology drug development.
"I am delighted to welcome Jean-Pierre to our Board of
Directors," said Dr. Helen Torley,
President and Chief Executive Officer. "His track record of success
in developing strategies that have resulted in global approvals for
some of the world's most important cancer drugs make him a strong
fit for Halozyme. We look forward to benefiting from his expertise
and counsel as we execute our strategy to advance PEGPH20 in
multiple tumor settings and expand ENHANZE™ collaborations."
Dr. Bizzari was Group Head, Clinical Oncology Development at
Celgene Corporation, a role he held since 2008. In this position,
Dr. Bizzari was responsible for Celgene's clinical development and
operations-statistics teams across the U.S., Europe and Asia/Japan
and has overseen the development and approval of a number of
leading oncology products including REVLIMID®
(lenalidomide), VIDAZA® (azacitidine),
ISTODAX® (romidepsin) and ABRAXANE®
(nab-paclitaxel). In addition, he was Chairman of Celgene's
hematology oncology development committee and a member of the
company's management committee.
Prior to his role at Celgene, Dr. Bizzari was the Vice
President, Clinical Oncology Development for Sanofi-Aventis where
he oversaw the approval of Eloxatin® (oxaliplatin),
Taxotere® (docetaxel) and Elitek®
(rasburicase). Prior to that he was Vice President, Clinical
Development Oncology for Sanofi-Synthelabo and had previously held
the same role for Rhône-Poulenc Rorer.
Dr. Bizzari is a member of the Scientific Advisory Board of
France's National Cancer Institute
and is a board member of Transgene. Jean-Pierre Bizzari is a Doctor of Medicine and
a graduate of the Nice Medical School and a specialist in oncology
(training in Toronto and
Montreal). Dr. Bizzari was also an
assistant in the medical oncology department at La
Pitié-Salpêtrière hospital in Paris.
About Halozyme
Halozyme Therapeutics is a
biopharmaceutical company dedicated to developing and
commercializing innovative products that advance patient care. With
a diversified portfolio of enzymes that target the extracellular
matrix, the Company's research focuses primarily on a family of
human enzymes, known as hyaluronidases, which increase the
dispersion and absorption of biologics, drugs and fluids.
Halozyme's pipeline addresses therapeutic areas, including
oncology, diabetes and dermatology that have significant unmet
medical need today. The Company has partnerships with Roche,
Pfizer, Janssen and Baxter.
Halozyme is headquartered in San Diego,
CA. For more information on how we are innovating, please
visit our corporate website at www.halozyme.com.
Safe Harbor Statement
In addition to historical
information, the statements set forth above include forward-looking
statements (including, without limitation, statements concerning
future actions relating to the development of PEGPH20) that involve
risk and uncertainties that could cause actual results to differ
materially from those in the forward-looking statements. The
forward-looking statements are typically, but not always,
identified through use of the words "believe," "enable," "may,"
"will," "could," "intends," "estimate," "anticipate," "plan,"
"predict," "probable," "potential," "possible," "should,"
"continue," and other words of similar meaning. Actual results
could differ materially from the expectations contained in
forward-looking statements as a result of several factors,
including unexpected developments in clinical trials (including
potential additional safety events), unexpected expenditures and
costs, unexpected results or delays in development and regulatory
review, regulatory approval requirements, unexpected adverse events
and competitive conditions. These and other factors that may result
in differences are discussed in greater detail in Halozyme's
Quarterly Report on Form 10-Q filed with the Securities and
Exchange Commission on November 10,
2014.
Investor Contact:
Schond Greenway
Halozyme Therapeutics
858-704-8352
ir@halozyme.com
Media Contact:
Susan Neath
Francis
212-301-7182
sfrancis@w2ogroup.com
Logo -
http://photos.prnewswire.com/prnh/20100302/LA63139LOGO
To view the original version on PR Newswire,
visit:http://www.prnewswire.com/news-releases/halozyme-appoints-jean-pierre-bizzari-md-to-board-of-directors-300023290.html
SOURCE Halozyme Therapeutics, Inc.